Drug Search Results
More Filters [+]

IMOVAX Polio

Alternative Names: IMOVAX Polio, Inactivated Poliomyelitis vaccine (IMOVAX)
Latest Update: 2022-05-09
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Austria | Bangladesh | Belgium | Bulgaria | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Malaysia | Mexico | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | South Africa | Spain | Taiwan | Tunisia | United Arab Emirates | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IMOVAX Polio

Countries in Clinic: Unknown Location

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Anus Diseases|Diphtheria|Healthy Volunteers|Hepatitis|Influenza, Human|Poliomyelitis|Tetanus

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2022-003923-17

P3

Active, not recruiting

Poliomyelitis

2025-06-09

2021-006686-37

P3

Active, not recruiting

Tetanus|Hepatitis|Poliomyelitis|Anus Diseases|Diphtheria|Influenza, Human

2023-08-08

CTR20160566

P3

Active, not recruiting

Healthy Volunteers

None

Recent News Events